KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Convertible Debt (2020 - 2025)

Esperion Therapeutics' Convertible Debt history spans 6 years, with the latest figure at $97.3 million for Q4 2025.

  • For Q4 2025, Convertible Debt rose 0.53% year-over-year to $97.3 million; the TTM value through Dec 2025 reached $97.3 million, up 0.53%, while the annual FY2025 figure was $97.3 million, 0.53% up from the prior year.
  • Convertible Debt reached $97.3 million in Q4 2025 per ESPR's latest filing, roughly flat from $97.1 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $272.5 million in Q3 2021 to a low of $96.7 million in Q4 2024.
  • Average Convertible Debt over 5 years is $221.4 million, with a median of $260.1 million recorded in 2022.
  • Peak YoY movement for Convertible Debt: soared 44.0% in 2021, then tumbled 63.06% in 2025.
  • A 5-year view of Convertible Debt shows it stood at $258.3 million in 2021, then increased by 0.63% to $259.9 million in 2022, then increased by 0.65% to $261.6 million in 2023, then plummeted by 63.02% to $96.7 million in 2024, then grew by 0.53% to $97.3 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Convertible Debt are $97.3 million (Q4 2025), $97.1 million (Q3 2025), and $97.0 million (Q2 2025).